MNPR — Monopar Therapeutics Share News
0.000.00%
Last trade - 00:00- $487.17m
- $352.87m
Brief: Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
U.S. RESEARCH ROUNDUP-Autodesk, Crowdstrike, Oshkosh
Monopar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Monopar Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Monopar Announces First Patient Enrolled In First-in-Human Phase 1 Trial For Novel Radiopharmaceutical MNPR-101-Zr
Brief: Monopar And Northstar Amend & Extend Collaboration
Brief: Monopar Announces CFO Succession
Brief: Monopar Announces Filing Of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Brief: Monopar Initiates Early-Stage Trial For MNPR-101-Zr In Advanced Cancer Patients
Monopar Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Monopar Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Brief: Monopar Therapeutics Says Got Letter From Nasdaq, Co Granted Extension To Aug 26 To Regain Compliance
Brief: Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
U.S. STOCKS ON THE MOVE-J.B. Hunt, Synopsys, DoorDash
U.S. STOCKS ON THE MOVE-Wayfair Inc, Remitly Global, Monopar Therapeutics
Brief: Monopar Therapeutics Announces Promising Pre-clinical Data For Its MNPR-101 Radiopharma Program Targeting Advanced Cancers
U.S. STOCKS ON THE MOVE-Coty, Planet Fitness, Quanta Services
Monopar climbs on 'promising' preclinical data from cancer treatment trial